KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial

NCT04844619 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Glaucoma
Neovascularization

Interventions

DRUG: 4mg/ml KDR2-2 suspension eyedrop
DRUG: 16mg/ml KDR2-2 suspension eyedrop

Sponsor

Sun Yat-sen University